Investigators used the Australian Cardiac Outcomes Registry to assemble a retrospective cohort of all Queensland residents undergoing TAVR between April 2018 and 27 March 2026. The study team assigned rurality by patient postcode using the Modified Monash Model (MMM) and grouped patients as urban (MMM1), regional (MMM2–4), or remote (MMM5–7). A total of 6,813 individuals were included, with 4,246 (62%) classified urban, 2,092 (31%) regional, and 475 (7%) remote. The authors stated the primary outcome as 12-month mortality, which they evaluated with Kaplan–Meier survival estimates and Cox proportional hazards models.
Twelve-month all-cause mortality did not differ between the rurality groups. The reported crude event counts were 211 deaths (5.0%) among urban patients, 103 deaths (4.9%) in the regional group, and 23 deaths (4.8%) in remote patients; χ2=0.991 and a log-rank P=0.929 were reported. Multivariable analysis produced concordant results: rurality category was not an independent predictor of 12-month mortality after adjustment. The dataset therefore indicates equivalent post-procedural survival up to one year among Queensland residents who underwent TAVR across urban, regional and remote classifications.
The cohort showed measurable baseline heterogeneity by place of residence. Regional and remote patients were younger at the time of procedure, yet carried greater comorbidity burden and presented with more severe aortic stenosis compared with urban counterparts. Paradoxically, the study team reported lower STS scores among regional and remote patients despite these adverse features. The registry-based data did not provide further granular details about referral intervals, symptom duration prior to presentation, or local diagnostic pathways. The authors reported these baseline contrasts directly from registry variables.
The authors tested multiple candidate predictors in multivariable Cox models. Variables that independently predicted higher 12-month mortality included higher clinical frailty score, non-transfemoral access route, elevated STS score, the presence of atrial fibrillation or flutter, and moderate–severe chronic lung disease. These factors were associated with outcome regardless of rurality group. The source did not report specific effect sizes, hazard ratios, confidence intervals, or full model coefficients within the abstract text; those details would need to be consulted in the full manuscript or registry tables.
Data for the analysis were provided by the Australian Cardiac Outcomes Registry under a data-use agreement. The study protocol received approval from the local Human Research Ethics Committee and James Cook University (HREC/2025/QCH/117308), and a waiver of consent to access registry data was granted. The authors declared no competing interests. They also reported that there was no funding or sponsor involvement in the study.
The authors emphasised an important limitation: registry data include only patients who reached and underwent TAVR. The dataset therefore cannot account for people who never entered the pathway — for example, older rural residents who face barriers to symptom recognition, referral, diagnostic workup, or procedural assessment. This potential selection bias may mask disparities in access to care upstream of the procedure. The source did not report on community-level referral rates, wait times, or the proportion of diagnosed severe aortic stenosis patients who did not progress to TAVR, and the abstract does not provide those denominators. Additional unanswered questions listed by the study team concern whether centralised regulatory requirements for TAVR centres affect diagnostic or referral access in rural settings; the registry-based analysis cannot directly address those process measures.
Limitations specific to the provided report include the absence—within the abstract text—of granular multivariable effect estimates, procedural detail breakdowns, and subgroup analyses beyond the MMM categories. Readers interested in hazard ratios, confidence intervals, or sensitivity analyses should consult the full preprint PDF or the underlying registry tables. The paper is a preprint and has not been peer reviewed; investigators and clinicians should interpret results in that context.